This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Vilma Yuzbasiyan-Gurkan, PhD; George J. Brewer, MD
Ann Arbor, Mich

Arch Ophthalmol. 1989;107(12):1723.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—We read the article by Dr Newsome and colleagues¹ with great interest. It was very exciting to learn that in such a well-designed, well-executed, and well-analyzed controlled study, zinc therapy had such a marked effect on reducing the progression of such an important and debilitating disease as macular degeneration. However, we were dismayed by the authors' emphasis on possible zinc toxicity. In their own terms, their abstract closes with, "Because of the pilot nature of the study and the possible toxic effects and complications of oral zinc administration, widespread use of zinc in macular degeneration is not now warranted." Elsewhere in the report the authors expresspecific concerns about anemia and worsening of cardiovascular disease.

Our dismay arises from our team having spent the last 20 years administering zinc in relatively high doses to various types of patients and having a very difficult time identifying toxic effects. . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?